Scholar Rock refiles at-the-market offering for up to $200 million

Scholar Rock Holding Corporation filed a new prospectus supplement on August 6, 2026 covering an at-the-market equity program with Jefferies LLC as sales agent. The arrangement stems from an Open Market Sale Agreement dated November 14, 2022, under which the company may sell common stock through Jefferies acting as agent, with total offering value now set at up to $200,000,000.¹

This filing raises the remaining shares available under the sales agreement back up to $200,000,000 and replaces a prior prospectus supplement dated November 14, 2025.¹ The company noted that as of this filing it had already sold shares under the sales agreement and prior prospectuses generating aggregate net proceeds of approximately $257.7 million, with no further shares to be sold under the superseded prior supplement.¹

Scholar Rock stock trades on Nasdaq under the ticker SRRK, closing at $45.85 per share on August 3, 2026.¹ Jefferies will be compensated up to 3.0% of gross proceeds from shares sold under the agreement.¹

Scholar Rock said it plans to use net proceeds, combined with existing cash, to support commercialization of apitegromab, build out commercial infrastructure and supply chain, advance clinical programs, and for general corporate purposes.¹ Apitegromab's BLA was resubmitted in March 2026 with two third-party fill-finish facilities included, and the FDA accepted it with a September 30, 2026 PDUFA action date.¹

The filing also disclosed that investors in the offering would face immediate dilution of $42.30 per share, based on an assumed offering price of $45.85 and a net tangible book value of $2.09 per share as of June 30, 2026.¹